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Abstract: Refractory ascites can occur in patients with various conditions. Although several 
procedures based on the reinfusion of ascitic fluid have been reported after the failure of bed 
rest, salt and water restriction, diuretics, intravenous administration of albumin, and repeated 
paracentesis, these procedures are performed for ascitic fluid removal without dialytic effect. 
In this study, a flow control reinfusion of ascites during hemodialysis (HD) was performed to 
demonstrate the efficacy of this method in a lupus patient with massive refractory ascites and 
respiratory and acute renal failure (ARF). The alleviation of ascites and ARF attests to the suc-
cess of the flow control reinfusion of ascites during HD. This procedure can control the rate of 
ascites and body fluid removal simultaneously during HD using the roller pump. In conclusion, 
with a normal coagulation profile, the procedure of flow control reinfusion of ascites during HD 
is an effective alternative treatment for the alleviation of refractory ascites with renal failure.
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Introduction
Refractory ascites can occur in patients with conditions such as liver cirrhosis, 
  congestive heart failure, nephrotic syndrome, and lupus serositis1 and in many cases 
cause abdominal discomfort and respiratory distress to the patient. The treatments 
for refractory ascites, eg, bed rest, salt and water restriction, diuretics, intravenous 
administration of albumin, and repeated paracentesis, are usually unsatisfactory. Several 
procedures based on the reinfusion of ascitic fluid have been performed for ascitic 
fluid removal.2–8 This report introduces the procedure flow control reinfusion of ascites 
into the dialyzer during hemodialysis (HD) (Figure 1A), by which a 34-year-old lupus 
patient with massive ascites, respiratory distress, and acute renal failure (ARF), who 
did not respond to diuretics, repeated paracentesis with intravenous albumin infusion, 
and HD, was successfully treated. Prophylactic fresh frozen plasma infusion, sequential 
ultrafiltration, and reduced dialysate temperature during HD in previous treatments did 
not prevent intradialytic hypotension. The patient’s symptoms were remedied by seven 
sessions of flow control reinfusion of ascites   during HD (Figure 1B, C).
Case
A 34-year-old female with systemic lupus erythematosus was admitted due to 
  progressive lower leg edema, massive ascites, and nausea after treatment of bed 
rest, salt and water restriction, diuretics, intravenous administration of albumin and 
  methylprednisolone, and repeated paracentesis for 2 months. On physical examina-
tion, her blood pressure was 127/82 mm Hg, pulse rate 84 beats/min, respiratory rate International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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20 breaths/min, and body temperature 37°C. Her abdomen 
was markedly distended and her lower extremities were 
severely edematous. The results obtained in laboratory 
investigations were as follows: white blood cells (WBCs) 
5.8 × 109/L (normal range 4.5–11 × 109/L), hemoglobin 
89 g/L (normal range 120–160 g/L), platelets 220 × 109/L 
(normal range 150–350 × 109/L), serum blood urea nitrogen 
(BUN) 13.5 mmol/L (normal range 2.5–7 mmol/L), creati-
nine 170 µmol/L (normal range 50–110 µmol/L), albumin 
19 g/L (normal range 37–53 g/L), alanine aminotransferase 
0.24 µkat/L (normal range 0–0.66 µkat/L), aspartate amin-
otransferase 0.60 µkat/L (normal range 0.08–0.76 µkat/L), 
C-reactive protein 0.286 mg/dL (normal range 0–0.5 mg/dL), 
complement 3 (C3) 0.4 g/L (normal range 0.8–1.5 g/L), 
complement 4 (C4) 0.1 g/L (normal range 0.2–0.4 g/L), 
and double-strand DNA (dsDNA) 263 IU/mL (normal 
range ,30 IU/mL). Urine protein   excretion was 4.86 g/day. 
Chest X-ray showed massive bilateral pleural effusion. The 
WBC count of ascitic fluid was 10/mm3. The serum–ascites 
albumin gradient was 1.4 mg/dL. The results of bacteria 
culture, acid-fast stain, malignant cell, and tuberculosis–
polymerase chain reaction of ascites were negative. The Dop-
pler of the main portal vein, inferior vena cava, major portal 
branches, and hepatic vein were patent without   obstruction. 
The abdominal computed tomography scan revealed mas-
sive ascites   (Figure 2A). The   echocardiogram showed no 
pericardial effusion and preserved left ventricle systolic 
function. Unfortunately, progressive massive ascite accumu-
lation gave rise to breathing difficulty and decreased urine 
output, despite an increase in serum albumin from 19 g/L 
to 28 g/L after the aforementioned treatments for 1 month 
at the   hospital. The serum BUN and creatinine levels were 
increased to 30.5 mmol/L and 720 µmol/L from 13.5 mmol/L 
and 170 µmol/L,   respectively. Disseminated intravascular 
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Figure 1 A) A paracentesis pigtail catheter was inserted into the abdominal cavity to draw out the ascites into the arterial chamber to be mixed with the blood by the 
flow control roller pump (pump B) during hemodialysis. This procedure allows for control of the flow of ascite reinfusion by the flow control roller pump (pump B) and the 
amount of body fluid removal by the ultrafiltration rate of the dialyzer simultaneously. B) The abdomen was distended by massive ascites. The superficial veins were also 
engorged before continuous infusion of ascites into the dialyzer to mix with blood. C) After ascite removal by ascite reinfusion into dialyzer, the distended abdomen and 
engorged veins disappeared.
Abbreviations: H. pump, heparin pump; IV. set, intravenous set; A. Ch, arterial chamber; As. Ch, ascites chamber; V. Ch, venous chamber.International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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coagulation (DIC) was within a normal range. Her lupus 
activity did not respond to plasma exchange, methylpred-
nisolone 1000 mg pulse therapy, oral prednisolone 60 mg 
daily, or cyclosporine 100 mg twice daily. Her renal failure, 
leg edema, and refractory ascites could not be controlled 
by HD due to frequent intradialytic hypotension, which 
could not be corrected by prophylactic fresh frozen plasma 
  infusion, sequential ultrafiltration, and reduction in dialysate 
temperature during HD. Therefore, continuous flow control 
reinfusion of ascites into a dialyzer during HD was designed 
to alleviate the ascites. A paracentesis pigtail catheter was 
inserted into the abdominal cavity and connected to a sterile 
three-way stopcock. When ascite reinfusion was planned, a 
set of dialysis tubing was connected with the sterile three-way 
stopcock to draw out the ascites at the speed of 12–15 mL/min 
(720–900 mL/h) into the dialyzer to mix with the blood by 
the roller pump   during HD. The mixed blood and ascites were 
then channeled into the systemic circulation during a 4-hour 
HD session (Figure 1A). The ultrafiltration rate of the dialyzer 
was maintained at around 1 L/h to allow fluid removal from 
the blood and infused ascites in each 4-hour HD session. 
After seven sessions of continuous reinfusion of ascites into 
the dialyzer during HD, ∼20 L of ascites were drawn out. The 
body weight and abdominal girth decreased from 50.2 kg to 
37 kg and from 92 cm to 72 cm, respectively (Figure 3). The 
serum albumin level increased from 30 to 35 g/L (Figure 3). 
There was no intradialytic hypotension, fever, gastrointestinal 
bleeding, or DIC. Her respiratory distress and general condi-
tion also improved after the procedures. The levels of comple-
ments C3 and C4 also increased from 0.4 g/dL to 0.7 g/dL 
and from 0.1 g/dL to 0.13 g/dL, respectively. After the ascites 
subsided, the paracentesis pigtail catheter was removed. 
A piece of omentum was obtained by peritoneoscopy for the 
evaluation of the cause of refractory ascites. The pathologic 
finding of the omentum was chronic inflammation with cell 
infiltration, congestion, and fibrosis (Figure 4).
In the following 60 months, the serum creatinine level 
was around 120 µmol/L on immunosuppressive agents. There 
were no further episodes of refractory ascites. The patient 
also had an increase in muscle mass.
Discussion
In our patient, liver cirrhosis, congestive heart failure, carci-
nomatous peritonitis, and bacterial peritonitis-related ascites 
were excluded by serial examinations. The refractory ascites 
AB
Figure  2  A)  Contrast-enhanced  CT  of  abdomen  revealed  massive  ascites. 
B) Contrast-enhanced CT taken after modified hemodialysis for 10 days. The scan 
at the same level as (A) reveals the disappearance of ascites.
Abbreviation: CT, computed tomography.
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Figure 3 The changes in body weight, abdominal girdle, and serum albumin after seven sessions of continuous infusion of ascites into the dialyzer during hemodialysis over 
9 days.
Abbreviation: BW, body weight; HD, hemodialysis.International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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caused by lupus serositis was most likely due to the high level 
of dsDNA, low serum level of C3/C4, and inflammatory 
omentum (Figure 4).
The patient’s refractory ascites, leg edema, and respiratory 
distress improved after seven sessions of continuous infusion 
of ascites into the dialyzer during HD after failure of other 
treatments, including bed rest, salt and water restriction, 
diuretics, intravenous administration of albumin, repeated 
paracentesis, sequential ultrafiltration, and reduced dialysate 
temperature during HD. The success of this treatment showed 
that the removed body fluid was replaced by the drawn out 
ascites at a speed of 12–15 mL/min (720–900 mL/h) concur-
rently during HD while ultrafiltration was set at around 1 L/h. 
There were 2.88–3.6 L of ascitic fluid from the abdomen 
infused into the dialyzer and a net 0.4–1.12 L of fluid removed 
from the systemic circulation during each 4-hour HD ses-
sion. A serum albumin level increase from 28 g/L to 35 g/L 
after seven sessions of continuous reinfusion was due to the 
infused ascites and protein into the systemic circulation dur-
ing HD (Figure 3). The increase in serum level of albumin 
might have also pulled the interstitial fluid into the intravas-
cular space via the increase in serum oncotic pressure.5,7,9 
Leg edema, pleural effusion, and refractory ascites were 
ameliorated by small negative fluid balance and increased 
serum albumin level during HD.
In this case, ARF occurred, along with the progressively 
worsening ascites and respiratory distress, but improved after 
the refractory ascites subsided. This implied that ARF was 
mostly related to the refractory ascite-induced hypovolemia 
and unstable hemodynamic status.
Ascite reinfusion has been reported in chronic HD 
patients with cirrhotic, lupus, or nephrogenic ascites.2–8,10–13 
In this case, ascitic fluid was infused into the dialyzer under 
flow control by the roller pump, and the fluid was removed 
from the systemic circulation simultaneously during HD. This 
procedure of flow control allowed adequate fluid removal 
without intradialytic hypotension.
Several procedures based on the reinfusion of ascitic fluid 
have been reported in chronic HD patients with cirrhotic, 
lupus, or nephrogenic ascites, eg, intravenous reinfusion of 
concentrated ascites, extracorporeal ultrafiltration of ascite 
fluid with peritoneal reinfusion, ascitic fluid concentration 
with blood reinfusion during HD, and peritoneovenous 
shunt.2–8,10–13 In comparison with those procedures, the flow 
control reinfusion of ascites during HD is rapid, easier, and 
effective. Ascitic fluid does not need to be concentrated 
before reinfusion. This procedure and McGill et al’s method13 
could simultaneously control the flow of ascite reinfusion by 
the flow control roller pump and the amount of body fluid 
removal by the ultrafiltration rate of dialyzer. The serum 
albumin level was increased after the infusion of protein-rich 
ascites into the systemic circulation during HD. The elevated 
serum level of albumin pulls the interstitial fluid into the 
intravascular space via increased serum oncotic pressure.
With the successful outcome of this case report, we 
believe that flow control reinfusion of ascites during HD 
is an effective alternative treatment for the alleviation 
of refractory ascites in patients with renal failure, who 
are unresponsive to bed rest, salt and water restriction, 
diuretics, intravenous administration of albumin, repeated 
paracentesis, sequential ultrafiltration, and reduced dialysate 
temperature during HD. Although not observed in this case, 
the potential adverse effects, such as fever, gastrointestinal 
bleeding, DIC, peritonitis, or septicemia, by the intravenous 
or intra-abdominal infusion of ascites should be kept in 
mind.14,15 The activation of fibrinolytic activity of ascites 
due to the relative plasminogen activator inhibitor type-1 
deficiency and enhanced basal tissue plasminogen activa-
tor has been reported.16–19 Therefore, clotting tests should 
be carried out before the procedure is initiated, and if the 
patient’s blood and ascites denote a fibrinolytic activity, the 
procedure should be considered hazardous and probably 
contraindicated.
In conclusion, the alleviation of ascites and ARF attest 
to the success of the procedure of continuous infusion of 
ascites into the dialyzer during HD. With normal coagulation 
function, it is an effective alternative treatment of refractory 
ascites, especially in patients with renal failure or who are 
unresponsive to bed rest, salt and water restriction, diuretics, 
intravenous administration of albumin, repeated paracentesis, 
Figure 4 An omentum biopsy shows chronic inflammatory cell infiltration and 
congestion.International Journal of Nephrology and Renovascular Disease
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sequential ultrafiltration, and reduced dialysate temperature 
during HD.
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